Treatment of lung cancer with orally administered Chinese herbal medicine: an evidence map between 1970 and 2020


This article was originally published here

Chin J Integr Med. 2022 Mar 3. doi: 10.1007/s11655-022-3465-3. Online ahead of print.


OBJECTIVE: By showing the complete picture of dual-arm controlled clinical research and systematic review evidence in the field of orally administered Chinese herbal medicine (CHM) for the treatment of lung cancer, to provide a reference for the future clinical research and indicate a direction for future systematic reviews.

METHODS: A comprehensive search of controlled clinical studies was performed for oral CHM treatment for lung cancer published from January 1970 to September 2020. Language was limited to Chinese and English. Relevant data were extracted, the quality of systematic reviews was assessed, and the search evidence was displayed visually.

RESULTS: Randomized controlled trials were the most common type of research design. Research sample sizes were generally small. Oral MHC has shown some curative benefits in the treatment of lung cancer. The key steps in oral CHM intervention for lung cancer are chemotherapy, radiotherapy and late palliative treatments. The advantageous outcomes of oral CHM treatment for lung cancer are short-term efficacy, quality of life, and adverse effects. The perioperative phase, overall survival, pharmacoeconomic evaluation and Chinese medicine decoctions are weak areas of research.

CONCLUSIONS: CHM has staggered and therapeutic benefits in the treatment of lung cancer. The overall methodological quality is mediocre and the level of evidence needs to be improved. There is a need for large-scale, standardized, and higher-quality research into the upper and lower areas of CHM treatment of lung cancer.

PMID:35243583 | DO I:10.1007/s11655-022-3465-3


Comments are closed.